Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Metabolism & Toxicology|August 28, 2010
Pharmacokinetic evaluation of fosaprepitant dimeglumineFrancheska Colon-Gonzalez, Walter K Kraft
Expert Review of Endocrinology & Metabolism|February 8, 2011
Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesityMichael A Valentino, Francheska Colon-Gonzalez, Jieru E Lin, et al.
Molecular Aspects of Medicine|October 30, 2012
Obesity pharmacotherapy: what is next?Francheska Colon-Gonzalez, Gilbert W Kim, Jieru E Lin, et al.
Expert Review of Clinical Pharmacology|June 14, 2011
Regulation of appetite to treat obesityGilbert W Kim, Jieru E Lin, Michael A Valentino, et al.
Biomacromolecules|November 28, 2007
Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriersEric A Simone, Thomas D Dziubla, Francheska Colon-Gonzalez, et al.
Clinical Pharmacology in Drug Development|March 27, 2020
Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy ParticipantsKeith Boundy, Yang Liu, Pratik Bhagunde, et al.
Nature Communications|May 16, 2013
Coordinated activation of the Rac-GAP β2-chimaerin by an atypical proline-rich domain and diacylglycerolAlvaro Gutierrez-Uzquiza, Francheska Colon-Gonzalez, Thomas A Leonard, et al.
International Journal of Antimicrobial Agents|January 14, 2023
A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participantsNa Liu, Xiaohong Wang, Jixiang Zhu, et al.
Antimicrobial Agents and Chemotherapy|December 8, 2020
A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese ParticipantsXiaohong Wang, Na Liu, Yudong Wei, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2018
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy ParticipantsElizabeth G Rhee, Matthew L Rizk, Nicole Calder, et al.
Pageof 2